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Oxytocin involves in chronic stress-evoked melanoma metastasis via -arrestin 
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Stress is associated with an increased risk of lung metastasis in melanoma. However, 
the underlying mechanism is elusive. Oxytocin (OXT), a neurohormone produced by 
the hypothalamus, plays a vital role in laboring induction and lactation. Emerging 
evidence suggests that OXT also regulates human emotions, social cognition, social 
behaviors and stress-related disorders. Here, we reported that a significant 
up-regulation of oxytocin receptors (OXTRs) was observed in malignant melanoma. 
The activation of oxytocin receptors (OXTRs) dramatically promoted migration, 
invasion and angiogenesis but not the proliferation of melanoma cells in vitro and in 
vivo via -arrestin 2-dependent ERK-VEGF/ MMP-2 pathway. Next, chronic restraint 
stress significantly elevated the plasma level of OXT. Notably, 21 days chronic 
restraint stress facilitated lung metastasis of melanoma and reduced overall survival in 
mice, which were largely abrogated by knocking down either OXTR or -arrestin 2. 
These findings provide evidence that chronic stress hormone-OXT promotes lung 
metastasis of melanoma via a -arrestin 2-dependent mechanism and suggest that 
OXT, a novel pro-metastasis factor, is a potential therapeutic target for melanoma. 
KEYWORDS: 
Stress; Melanoma; metastasis; oxytocin; -arrestin  
Importance of the Study 
Oxytocin, a neuropeptide produced in the hypothalamus that is involved in lactation 
and parturition, play a vital role in chronic stress-evoked melanoma metastasis via 
-arrestin 2-mediated ERK signaling pathway, which provides a potential therapeutic 
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Melanoma is the most deadly type of skin cancer and its incidence rate is rising 
worldwide. Presently, there are no effective therapies to prevent melanoma 
metastasis. As the only Food and Drug Administration (FDA)-approved melanoma 
adjuvant therapy, interferon-alpha only showed a meager 5-year overall survival 
benefit of 1%–3% (1). Despite recent advances in immunotherapy, most metastatic 
melanoma patients still die from their own disease, with an average survival time of 
23 months (2,3). For patients with advanced melanoma, due to its poor clinical 
prognosis and lack of effective treatment, it is necessary to develop and implement 
new methods to prevent metastatic recurrence of this cancer. A growing body of 
literature suggests that stress can affect cancer progression. Chronic stress increases 
the spread of metastatic cancer cells from primary breast tumors to the lungs (4). 
Stress hormones promote EGFR inhibitor resistance in the treatment of non-small cell 
lung cancer(5). If cancer patients are socially isolated or separated from their spouses, 
their survival rate decreases markedly (6,7). Instead, social support can improve the 
prognosis of cancer patients (8). Chronic restraint stress promotes melanoma lung 
metastasis by inhibiting the immune system (9,10). However, there are no rational 
explanations for the poor outcomes of stress-associated melanoma patients so far. 
Oxytocin (OXT), a neurohormone produced by the hypothalamus, plays a vital role in 
laboring induction and lactation. Emerging evidence suggests that OXT also regulates 
human emotions, social cognition, social behaviors (11) and stress-related disorders 
(12). Hormone OXT also belongs to stress hormones and is released in response to 
several stress stimuli (13). After exposed to repeated restraint stress, the 
concentrations of OXT in plasma was significantly increased (14). Therefore, we 
hypothesized that stress hormone-OXT involves the stress-promoted 
melanoma pulmonary metastasis. Recently, an additional new role of OXT has been 
identified in neoplastic pathology. In tumor, OXT acts as a grow regulator, through 
the activation of a specific G-coupled transmembrane receptor, the oxytocin receptor 
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melanoma is unclear, and whether OXT signals will be a target for melanoma 
treatment remains unclear. The purpose of this study was to investigate the role of 
OXT in the lung metastasis of stress melanoma. Herein, we demonstrated that OXTR 
activation increased melanoma cells migration and invasion in vitro, and promoted 
lung metastasis of melanoma in vivo by stimulating ERK1/2 phosphorylation and 
MMP-2 and VEGF production, which was abrogated with knockdown of either 
OXTR or -arrestin 2. The findings of present study shed some light on the 
mechanism of the poorer outcomes of the stress-related promotion of 
melanoma metastasis, suggesting OXT targeting might be a new strategy for 
melanoma therapy.  
Materials and methods 
Collection of malignant melanoma samples 
All specimens were confirmed as malignant melanoma by pathological diagnosis. All 
patients involved in this study received no radiation therapy or chemotherapy before 
surgical resection. The study included 7 females and 8 males, ranging in age from 41 
to 71 years with a mean age of 61 years. The clinicopathological information is 
summarized in Supplementary Table 1. Tissues were snap frozen in liquid nitrogen, 
and then stored at -80°C before use. 
Measurement of OXT 
One week after stress, mice (n=8) were anesthetized, blood was collected using a 
pre-chilled 1ml EDTA tubes from the caudal vein. Plasma (200l) was isolated by 
centrifugation at 1800 rcf, 15 minutes at 4℃. OXT contents were quantified in 
duplicates using a commercial OXT ELISA kit (Enzo Life Sciences, NY, USA). 
Cell culture and reagents 
Both murine B16F10 (catalog number: TCM 2) and human A375 (catalog number: TCHu155) 
were purchased from Typical Culture Preservation Commission Cell Bank, Chinese Academy 
of Sciences (Shanghai, China) in 2016 and 2015, respectively (Shanghai, China). Cells were 
tested and authenticated by karyotyping analysis on 1 March 2017. A375 cells were cultured 
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U/mL penicillin and 100 μg/ml streptomycin. The B16F10 cells were cultured in RPMI 1640 
(Hyclone Co) supplemented with 10 % FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. All cell lines were propagated at 37°C in an atmosphere containing 5% CO2. 
Primary antibodies for OXTR, MMP2 and VEGF were purchased from Abcam (Austin, TX), 
those for β-arrestin 1, β-arrestin 2, Erk and p-ErK were purchased from CST (Beverly, MA), 
that for b-actin was from Sigma-Aldrich (St Louis, MO). OXT was purchased from 
Sigma-Aldrich (St Louis, MO). 
Xenograft murine model 
For orthotopic mouse tumor model, 5x10
5 
B16F10 melanoma cells were injected s.c. 
into right hind flank of 6-week-old male C57BL/6 mice to develop melanoma. After 
one week of inoculation, mice with approximate tumor size were divided into two 
groups and administered intraperitoneally with normal saline or OXT (0.1 mg/kg/d) 
for 2 weeks. The tumor volume was calculated according to the formula (length × 
width
2
)/2 (16). Three weeks after tumor inoculation, they were then sacrificed for 
evaluating primary tumor size and weight. For the chronic stress model, we used a 
previously described and well-defined restraint stress procedure to induce symptoms 
of stress(17). In this model, mice are securely restrained in a movement-restricted 
space for 21 days to 2 hours of restraint in an acrylic cylindrical animal restrainer with 
holes that permit the restrainer to be adjusted according to the size of the subject. The 
restrainer allows unlimited breathing but restricts the movement of the limbs. After 
being restrained, the mice were returned to their home cage and given food and water. 
In all experiments, 5×10
5
 B16F10 cells were injected via tail vein (to study 
metastasis) in mice 1 week after the restraint stress procedure began. After 14 days, 
the animals were killed by cervical dislocation, and the numbers of tumor nodules of 
lung metastases were noted by researchers blinded to the groups. The lungs were 
harvested for immunohistochemical analysis. Following the same procedure, the 
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The siRNA sequence targeting mouse β-arrestin 2 
5′-AAGGACCGGAAAGUGUUCGUG-3 is reported elsewhere(18). β-arrestin 2 
shRNA (shβ-arr2) plasmid was constructed by Genechem (Shanghai, China). OXTR 
shRNA plasmid (shOXTR) and control plasmid were purchased from Genechem 
(Shanghai, China). Transfections were performed in 24-well culture plates using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Two days after transfection, B16F10 cells were selected by 1μg/mL 
puromycin (Sigma-Aldrich, StLouis, MO). The expression of β-arrestin 2 and OXTR 
after transfection was detected by Western blot. 
Western blot and immunocytochemical analysis 
For Western blot analysis, cells were lysed in lysis buffer [50 mmol/L Tris (pH 7.5), 
100 mmol/L NaCl, 1 mmol/L EDTA, 0.5% NP40, 0.5% Triton X-100, 2.5 mmol/L 
sodium orthovanadate, 10 μl protease inhibitor cocktail, 1 mmol/L 
phenylmethylsulfonyl fluoride] for 30 min at 4°C. Total proteins were fractionated by 
SDS-PAGE and transferred onto nitrocellulose membrane. The membranes were then 
incubated with appropriate primary antibodies (OXTR, MMP2,VEGF, β-arrestin 1, 
β-arrestin 2, Erk and p-ErK), followed by incubation with a secondary 
HRP-conjugated antibody. For histopathologic analysis, lung samples were fixed in 
4% paraformaldehyde immediately after being harvested and then paraffin-embedded. 
Lung samples were subjected to antigen retrieval treatment by microwave prior to 
blocking with sequential peroxidase and goat serum block. After incubation for the 
diluted primary antibody, a secondary HRP-conjugated antibody was used. For 
protein levels, the slides were stained with respective antibodies and staining intensity 
assessed semi-quantitatively. In short, 5 random ﬁelds were chosen per slide and 
scored from 0 to 4 on intensity, and 0% to 100% on distribution of positive staining of 
tumor tissues. The ﬁnal results per group are presented in the accompanying graph 
with representative pictures for each group.  
Gelatin zymography analysis 
The effects of OXT on the gelatinolytic activities of MMP-2 were examined by 
gelatin zymography. A375 cells were treated with various concentrations of OXT for 
48 hours in serum-free medium. Serum-free supernatants were then harvested and 






/carcin/advance-article-abstract/doi/10.1093/carcin/bgz064/5421789 by Laurent N











centrifuged to remove cellular debris. Protein concentrations were determined with 
the bicinchoninic acid assay protein reagent kit (Sangon, Shanghai, China). An equal 
amount of protein (20 μg) from each treatment was diluted with the loading buffer 
and fractionated on 10% SDS ⁄ PAGE containing 1 mg/mL gelatin A (Sigma 
Chemical Co.). After electrophoresis, the gels were stained with 0.1% Coomassie 
Brilliant Blue and destained with 45% methanol, 10% (v ⁄ v) acetic acid until clear 
bands suggestive of gelatin digestion were present.  
Cell proliferation studies 
The proliferation of B16F10 and A375 cells was assessed by Cell Counting Kit-8 
(CCK-8, Beyotime, C0038) assay according to the protocol recommended by the 
manufacturer. The approximate 2000 cells were seeded in each well of 96-well plates 
with 100 L medium. OXT (10-7 M) was added to each well. After being 
incubated for 1, 2, 3 and 4 days, 10 L CCK-8 solution was added into each well. 
Cells were then incubated for another 4 h at 37℃. The absorbance was measured by a 
microplate reader at the wave length of 450 nm. In each experiment, six parallel wells 
were set up. 
Wound-healing assay 
B16F10 cells were seeded onto a six-well culture plate and cultured to a subconfluent state in 
complete medium. Cell monolayers were linearly scraped with a P-200 pipette tip (250-μm 
width). Cells detached from the bottom of the well were mildly aspirated and incubated in 
serum-free medium containing different concentrations of OXT (0,10-9,10-8,10-7,10-6 
mol/L) for 24 hours. The width of the scratch was microscopically monitored at various time 
points and quantified in terms of the difference between the original width of the wound and 
the width after cell migration. The percentage of wound closure [(original width-width after 
cell migration)/original width] was calculated. The width of the wound was measured using 
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A complementary transwell migration assay was performed by employing a modified Boyden 
chamber (Corning Costar) containing a gelatin-coated polycarbonate membrane filter (pore 
size, 8 μm). A total of 2×104 cells in 500 μL of culture medium containing various 








 mmol/L) were added to the upper chamber, and 
the lower chamber contained culture medium with 10% FBS to stimulate cell migration. The 
migration assays were incubated for 24 hours at 37°C in 5% CO2, and then the cells were 
stained with crystal violet. Cells on the undersides of the filters were observed under a 
microscope at a magnification of 200 x and counted.  
Matrigel in vitro HUVEC tube formation assay 
The in vitro tube formation assay was performed according to the manufacturer’s 
recommendation. Briefly, growth factor-reduced Matrigel, after being thawed on ice, 
was plated in pre-cooled 12-well chamber. After solidification of Matrigel (30 min 
incubation at 37°C), HUVECs were trypsinized and seeded (5×10
4
 cells per well) in 
each well with 1640 medium alone (control sample) or 1640 supplemented with 
cell-free culture supernatants from different treatment (1:1, v/v). Each sample was 
added in duplicate wells. The chambers were then incubated at 37°C for 24 hours. 
After incubation and fixation phases, the tube formation process involving HUVECs 
adhesion, migration, differentiation and growth was scored using an inverted 
phase-constrast microscope and measured using Image-Pro Plus 6.0. 
Statistical analysis 
Continuous variables were recorded as mean ± SD and analyzed by Student’s t test. 
For data with non-normal distribution or heterogeneity of variance, median (range) 
was shown and comparison was examined by Mann-Whitney U test or 
Kruskal-Wallis H test. All survival analyses were estimated from Kaplan-Meier 
curves. The log-rank test was used to assess the significance of univariate survival 
analyses. Statistical analysis of the results was performed using GraphPad StatMate 
software (GraphPad Software, Inc, San Diego, CA). The two-sided P-values <0.05 
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The OXTRs were expressed in melanoma cells and significantly upregulated in 
malignant melanoma compared to controls. 
Next, we examined whether OXTRs were expressed in melanoma cells. As expected, Western 
blot analyses of cultured mouse (B16F10) and human (A375) melanoma cells, human 
malignant melanoma tissues and the paratumor tissues with OXTRs antibody detected the 
expression of OXTRs (Fig.1A). The melanoma cells contained high level of OXTRs protein. 
Strikingly, the OXTR protein levels of human melanoma tissue samples were significantly 
upregulated compared with the paratumor tissues (n=5), which were confirmed by 
immunochemistry analyses (n=10, Fig.1B). These above results indicate that OXT signaling 
is in the development of melanoma. 
OXT promoted migration, invasion and angiogenesis but not proliferation of 
melanoma cells in vitro and in vivo. 
Next, we investigated the role of OXT in the migration, invasion and angiogenesis of 
melanoma cells. The transwell migration assay and wound healing assay revealed that 
OXT markedly increased the migration and invasion of both B16F10 mouse 
melanoma cells and A375 human melanoma cells in dose-response manner (P 
<0.05;Fig.2A-B). It is well known that tumor growth and metastasis depend 
on angiogenesis (19). The tube formation assay is one of the most widely used in vitro 
assays to model the reorganization stage of angiogenesis. Effect of OXT on tube 
formation using an in vitro angiogenesis assay in growth factor-reduced Matrigel. 
Tube formation was observed after 24 h and total tubular length was calculated (m). 
As expe ted, the tube formation assay revealed that the supernatants of A375 
melanoma cells treated with OXT markedly  enhanced the formation of tube-like 
structures compared with controls (P < 0.05; Fig. 2C). The angiogenic response was 
dose dependent. These results suggested that OXT promotes angiogenesis  in vitro. 
To verify whether OXT affects the migration and invasion of melanoma cell in vivo, 
we utilized a murine xenograft model of spontaneous metastases of B16F10 mouse 
melanoma cells. The administration of OXT largely enhanced the lung metastasis of 
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survival in mice with melanoma lung metastasis compared with the PBS control 
group (n = 8, P =0.056; Fig.3B). However, atosiban, an antagonist of OXTR had no 
effect on the lung metastasis and the survival rate (n = 8-9, P >0.05; Fig.3B).  
To observe whether activation of OXTR affects proliferation in melanoma cells, we treated 
melanoma cells with OXT or vehicle in vitro (P > 0.05;Fig.3C), or injected s.c. equal numbers 
of B16F10 mouse melanoma cells into the right hind flank of host C57BL/6 mice (Fig. 3D) 
followed by successive injection of OXT (0.1mg/kg/d). B16F10 is a selective variant cell line 
obtained from pulmonary metastasis of a melanoma, syngeneic to black C57BL/6 mice (20). 
However, OXT did not affect cancer cell proliferation(Fig. 3C) and tumor growth(n = 5, P > 
0.05; Fig. 3E). 
OXT stimulated the production of VEGF and MMP-2 and promoted metastasis via 
a -Arrestin2-dependent ERK1/2 activation in melanoma cells. 
To explore the mechanism of OXT-induced metastasis, firstly we detected the 
production of VEGF and MMP-2. Western blot assay revealed that OXT 
dose-dependently promoted the production of VEGF and MMP-2 in both B16F10 
mouse melanoma cells and A375 human melanoma cells, and led to robust ERK1/2 
activation (Fig. 4 A). Using g latin zymography analysis, we further confirmed OXT 
increased the MMP-2 activities of melanoma cells in dose-dependent manner 
(Fig.4B). -arrestins have been shown to bind several signaling proteins, including 
Src (21), ERK1/2(22-24) and JNK3 (25) in an agonist-dependent manner. To assess 
the importance of -arrestin 2 in mediating the G protein independent activation of 
ERK1/2, we used the siRNA interference to down-regulate the expression of 
endogenous -arrestin 2 and examined ERK1/2 activation by OXT. Silencing either 
OXTR or β-arrestin 2 largely suppressed the expression of OXTR or β-arrestin 2 in 
melanoma cells (Fig. S1). Down-regulation of -arrestin 2 expression by siRNA 
transfection abolished the ERK1/2 activation induced by OXT in B16F10 mouse 
melanoma cells (Fig. 4C). Notably, the down-regulation of arrestin 2 expression by 
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treatment (Fig. 4C). This finding indicates that the G protein-independent activation 
of ERK1/2 evoked by OXT is completely dependent on -arrestin 2. Because 
-arrestin 1 was not expressed in B16F10 melanoma cells (Fig. S2), these results 
suggest that -arrestin 2, not -arrestin 1, is the major form of -arrestin mediating 
OXT-induced G protein-independent ERK1/2 activation.  
Chronic restrain stress promoted melanoma lung metastasis, which were largely 
abolished by knocking down either OXTR or β-arrestin2.  
To explore the role of stress in lung metastasis of melanoma cells, we utilized a 
repeated restrain stress mouse model (Fig.5A). As expected, restrain stress 
significantly promoted the melanoma lung metastasis (n=8, P < 0.05; Fig.5B) and 
reduced the survival of mice with metastatic cancer (n=8, P < 0.05;Fig.5C) compared 
with the vehicle control group. Notably, the plasma OXT level was markedly elevated 
after exposed to the chronic restrain stress compared with the vehicle control group 
(n=8, P<0.05;Fig.5D). Down-regulation of OXTR or β-arrestin 2 expression by 
siRNA transfection markedly inhibited the promotion of migration and invasion of 
B16F10 melanoma cells induced by OXT in vitro (Fig. 6A-B). Importantly, 
knockdown of either OXTR or β-arrestin2 in tumor cells significantly inhibited the 
chronic stress-promoted lung metastasis and extended survival in mice compared with 
stress group (n = 8, P < 0.05;Fig. 6C). Immunohistochemistry staining of lung 
metastasis samples showed the chronic restraint stress up-regulated the ERK1/2 
phosphorylation and the expression of OXTR, MMP2 and VEGF in B16F10 
melanoma cells. Strikingly, down-regulation of either OXTR or β-arrestin 2 
expression by siRNA transfection significantly diminished phosphorylated ERK1/2 
and the production of MMP-2 and VEGF (Fig. 6D). 
Discussion 
Our results demonstrate that chronic stress promotes melanoma lung metastasis which 
is mediated by OXT via -arrestin 2 G protein-independent pathway. It is known that 
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expand the understanding of these processes that regulate melanoma cancer 
metastasis, indicating a novel strategy for inhibiting metastatic spread through 
targeted inhibition of OXTR signaling pathway. 
OXTR and its transduction mechanisms 
OXT exerts its biological effects through binding to OXTR, which belongs to a family 
of seven membrane-spanning receptors that transduce signals through G proteins. The 
coupling of OXTR with Gq results in the activation of PLC, the effector of 
phosphoinositide signaling system. Several literatures support the conclusion that 
PLC is the major effector enzyme for transduction of OXT signaling in cellular 
functions (29,30). The oxytocinergic system (OXT and OXTR) exists in various 
neoplastic cells, where it may stimulate or inhibit cell proliferation. OXTRs are 
expressed or over-expressed in cells of several tumor types such as breast and 
endometrial carcinomas (31-34), prostate carcinomas (35), neuroblastomas and 
glioblastomas (36), osteosarcomas (37), choriocarcinomas (38), and small-cell lung 
carcinoma (39). OXTRs were found in the most of ovarian carcinoma tissues (40). 
Moreover, all OXTRs in cancer cells are structurally identical with OXTRs in healthy 
cells and have the same ability to bind OXT (41). Here we first show that OXTR is 
expressed in melanoma cells. Importantly, malignant melanoma over-expressed 
OXTRs. Therefore, in vitro and in vivo, OXTRs activation significantly promoted the 
metastasis of melanoma, but did not promote cell proliferation. Previous studies have 
shown that OXT inhibits the proliferation of epithelial, nerve and bone derived tumor 
cells in vitro. In turn, OXT was found in tumor cells derived from trophoblasts and 
endothelial cells to promote cell proliferation (15,34,38). Localization of OXTR 
within the cell membrane was found to play a critical role in determining the effect of 
OXT of cell growth. When the OXTR is located outside lipid rafts, OXTR stimulation 
inhibits cell growth. In contrast, activation of OXTR in lipid rafts stimulates cell 
growth (42). Surprisingly, OXT did not exert any effect on proliferation of melanoma 
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Apart from traditional G-protein dependent signal pathway, -arrestin mediated 
G-protein independent pathway has been well studied (43). In addition to its role in 
mediating desensitization of GPCRs, -arrestin has also recently been identified to 
mediate GPCR-stimulated intracellular signaling (44-49). Examples of GPCRs that 
show -arrestin-mediated signaling are the parathyroid receptor (50) , angiotensin II 
type 1A receptor (49), 1-and 2 adrenergic receptor (47,48) and vasopressin V2 
receptor (51). Notably, -arrestin also mediates OXTR signaling (52). Following 
agonist stimulation of the OXTR, GPCR kinases phosphorylation of the receptor 
allows for the recruitment and binding of -arrestin. -arrestin recruitment to the 
OXTR leads to receptor internalization, uncoupling the receptor from G proteins, 
blocking further signaling. The molecular mechanism by which -arrestin transduces 
a signal appears to be through its scaffold function, which has been best characterized 
for the MAPK pathway (53).   
OXR/-arrestin 2-ERK signal pathway in melanoma metastasis 
To determine whether the -arrestin-dependent manner mediates OXT-induced 
melanoma cells migration and metastasis, we performed -arrestin loss-of-function 
experiments in vitro and in vivo. B16F10 melanoma cells transfected with siRNA 
directed against -arrestin 2 demonstrate decreased ERK phosphorylation following 
OXT treatment. Because -arrestin1 is not located in melanoma cells, we draw a 
conclusion that only -arrestin-2 is necessary for -arrestin-dependent ERK signaling 
from the OXTR activation in melanoma cells. The present studies first revealed 
-arrestin2 is involved in OXT-stimulated melanoma metastasis. However, our results 
does not rule out the possibility that traditional G-protein dependent pathway also 
involves in OXT-induced ERK activation. An important implication of this work is 
that the conformations of OXTR induced by OXT is competent to activate ERK1/2 
via -arrestin 2, but not able to activate G proteins.  
Metastasis is a major cause of cancer morbidity and mortality.Multiple host cell types 
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a new target for anti-metastasis therapy.Neuroendocrine kinetics has the potential to 
regulate the expression of genes of various cell types in tumor microenvironment. 
Interestingly, our current study suggests that in mouse melanoma models, inhibiting 
stress promotes melanoma metastasis and inhibits survival, consistent with previous 
studies (9,10). Strikingly, genomic knockdown of OXTR or -arrestin 2 inhibited or 
even cured the melanoma metastasis, respectively.  
Conclusions  
These findings suggest that increased OXT under stress may contribute to 
stress-related melanoma metastases. Therefore, as far as we know, it first provides a 
possible explanation for promoting melanoma metastasis under these conditions. 
Clinically, current data suggest that localized targeting of t mor-associated OXTR 
signal pathway (for example, with antagonists or anti-oxtr antibodies) may constitute 
a new auxiliary strategy to minimize melanoma metastasis.  
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Fig.1 OXTRs were expressed in melanoma cells and significantly upregulated in 
malignant melanoma. 
(A) Western blot analyses of cultured mouse (B16F10) and human (A375) melanoma 
cells, human malignant melanoma and paratumor tissues with antibodies to OXTR. 
Uterus: positive control. Notably, the expression of OXTR in malignant melanoma 
was significantly upregulated compared with paratumor tissues (n=5). (B) The 
representative immunohistochemical staining of OXTR of samples from   malignant 
melanoma and paratumor tissues  (n=10). The OXTR was overexpressed in 
malignant melanoma compared to paratumor tissues. Black arrows show 
Melanocytes.  
Fig.2 Effect of OXT on melanoma cell migration and angiogenesis activity in vitro.  









 M of OXT and allowed to migrate for 24 hours; then, the migrated 
cells were stained with crystal violet. The graphs depict the mean ± SD of three 
independent experiments. *, P< 0.05. (B) The effects of OXT on B16F10 and A375 
cells migration ability were plotted as the percentage of wound closure. The graphs 
depict the mean ± SD of three independent experiments. *, P < 0.05. (C) 
Angiogenesis was measured by in vitro tube formation assay. HUVECs were cultured 
with supernatants of A375 cells treated with serial concentration OXT on Matrigel. 
The degree of tube formation was quantified by Image-Pro Plus 6.0. The graphs 
depict the mean ± SD of three independent experiments. *, P < 0.05. 
Fig.3 Effect of OXT on melanoma lung metastasis and proliferation in vivo and in 
vitro.  
(A) Three days after B16F10 cell injection, mice divided randomly into three groups 
and treatment with OXT, atosiban or PBS for 1 week. 14 days after B16F10 cell 
injection, the animals were killed by cervical dislocation and the lungs were 
harvested. Representative images and the quantification of the metastatic foci of the 
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mice treatment with PBS, atosiban, or OXT followed by i.v. injection of B16F10 cells 
(n= 8).  
(C) The approximate 2000 cells were seeded in each well of 96-well plates with 100 
L medium. OXT (10-7 M) was added to each well. The proliferation of B16F10 and 
A375 cells was assessed by Cell Counting Kit-8 assay. After being incubated for 1, 2, 
3 and 4 days, 10 L CCK-8 solution was added into each well. Administration of 
OXT did not affect the proliferation of melanoma cells in vitro. (D) Three weeks after 
injection with 1x10
6
 B16F10 tumor cells into the inguinal area of host mice, the tumor 
size or weight were measured. (E) Administration of OXT (0.1mg/kg/d) did not affect 
the tumor size or tumor weight (n=5). n.s.: No significance.  
Fig.4 OXT enhances the production of VEGF and MMP2 via a β-arrestin 
2-dependent ERK.  








 M of OXT for 
48 hours. The cells were lysed and processed on a Western blot and probed for p-ERK 









 M of OXT for 48 hours. MMP2 activities in OXT-treated cells were detected 
using gelatin zymography analysis. (C) Control and -arr2 down-regulating B16F10 
cells were treated for 0 or 10
-7
 M of OXT for 48 hours. Phosphorylated ERK 
(p-ERK), total ERK (tERK), MMP2 and MMP9 were measured by Western blot. 
Mean densitometry from three independent experiments demonstrated that OXT 
increased p-ERK signaling (* P< 0.05), but the response was diminished in -arrestin 
2 down-regulating cells compared with control cells († P< 0.05, -arrestin 2 
down-regulating cells receiving OXT compared with control cells receiving OXT). 
Fig.5 Chronic stress remodels OXT level to promote lung metastasis of 
melanoma.  
(A)Schematic representation of the chronic stress paradigm. (B) Representative 
photograph of pulmonary metastatic foci produced 14 days after intravenous injection 
of B16F10 cells. The quantification of the metastatic foci indicated that stress mice 
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0.05. (C) Survival of stress mice and control mice. (D) ELISA of plasma OXT level in 
control mice and mice subjected to daily restraint stress (n = 8). *P < 0.05. 
Fig.6 Effect of silencing OXTR or β-arrestin2 on stress-promoted melanoma 
metastasis in vivo 
B16F10 cells were stably transfected with sharr2, ShOXTR or control. The effect of 
down-regulation of OXTR or -arrestin 2 on B16F10 cells treated with OXT was 
detected by in vitro Wound-healing assay (A) and invasion assay (B). Male mice were 
subjected to daily restraint stress for 1 week and then injected with B16F10 cells 
stably transfected with sharr2, ShOXTR or control. Two weeks after B16F10 cell 
injection, mice were euthanized and the number of nodules were noted. OXTR or 
-arrestin2 down-regulation signiﬁcantly (P<0.05) improved the prognosis of 
chronically stressed tumor bearing animals (n =8).The Kaplan-Meier survival curve 
was depicted (C).  (D) Immunohistochemical staining of lung metastasis samples 
showing the effects of chronic restraint stress on ERK phosphorylation, MMP2 and 
VEGF. OXTR or -arrestin 2 down-regulation signiﬁcantly (P < 0.05) diminished 
phosphorylated ERK, MMP-2 and VEGF production. All photographs were taken at 
400×magnification. The bars in the graphs correspond sequentially to the labeled 
columns of the images at left. Continuous variables were recorded as mean ± SD. 
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